- Home
- SERV vs ARVN Comparison
SERV vs ARVN Comparison
Compare SERV & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SERV | ARVN |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.2M | 781.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SERV | ARVN |
|---|---|---|
| Price | $8.46 | $11.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $18.60 | $15.35 |
| AVG Volume (30 Days) | ★ 3.7M | 699.4K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $908.60 | N/A |
| Revenue Next Year | $183.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.66 | $5.90 |
| 52 Week High | $18.64 | $14.22 |
Technical Indicators
Market Signals| Indicator | SERV | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 45.05 |
| Support Level | $8.02 | $11.07 |
| Resistance Level | $11.08 | $14.03 |
| Average True Range (ATR) | 0.56 | 0.63 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 33.81 | 43.74 |
Price Performance
Historical ComparisonAbout SERV Serve Robotics Inc.
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.